Tumor-secreted IFI35 promotes proliferation and cytotoxic activity of CD8+ T cells through PI3K/AKT/mTOR signaling pathway in colorectal cancer

A large proportion of the patients with cancer do not respond to immunotherapies. Recent studies suggested an important role for tumor-infiltrating cytotoxic T lymphocytes (CTL) in enhancing response to immunotherapy. Here, we aim to identify gene that induce proliferative and cytotoxic states of CD...

Full description

Saved in:
Bibliographic Details
Published inJournal of biomedical science Vol. 30; no. 1; pp. 47 - 19
Main Authors Li, Peisi, Zhou, Dawang, Chen, Dongwen, Cheng, Yikan, Chen, Yuan, Lin, Zhensen, Zhang, Xi, Huang, Zhihong, Cai, Jiawei, Huang, Wenfeng, Lin, Yanyun, Ke, Haoxian, Long, Jiahui, Zou, Yifeng, Ye, Shubiao, Lan, Ping
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 28.06.2023
BioMed Central
BMC
Subjects
1-Phosphatidylinositol 3-kinase
AKT protein
Animal models
Animals
Antibodies
Anticancer properties
Antigens
Antineoplastic Agents
Biomarkers
CD8 antigen
CD8+ T cells
CD8-Positive T-Lymphocytes
Cell culture
Cell growth
Cell proliferation
Colon cancer
Colonic Neoplasms
Colorectal cancer
Colorectal carcinoma
Cytotoxicity
Effectiveness
Flow cytometry
Humans
IFI35
Immunodeficiency
Immunohistochemistry
Immunotherapy
Interferon regulatory factor 7
Laboratory animals
Lymphocytes
Lymphocytes T
Metastases
Mice
Microenvironments
Phosphatidylinositol 3-Kinases
Proteins
Proteomics
Proto-Oncogene Proteins c-akt - genetics
Signal Transduction
Stat1 protein
T cells
TOR protein
TOR Serine-Threonine Kinases - genetics
Toxicity
Tumor Microenvironment
Tumors
γ-Interferon
China
CD8+ T cells
IFI35
Immunotherapy
Colorectal cancer
Online AccessGet full text

Cover

Abstract A large proportion of the patients with cancer do not respond to immunotherapies. Recent studies suggested an important role for tumor-infiltrating cytotoxic T lymphocytes (CTL) in enhancing response to immunotherapy. Here, we aim to identify gene that induce proliferative and cytotoxic states of CD8 T cells, and to investigate its effect on CAR-T cells against colorectal cancer. Correlation between the expression of IFI35 with the activation and cytotoxicity of CD8 T cells was assessed with TCGA and proteomic databases. Then we constructed murine colon cancer cells over-expressing IFI35 and tested their effect on anti-tumor immunity in both immunodeficient and immunocompetent mouse models. Flow cytometry and immunohistochemistry were performed to assess the immune microenvironment. Western blot analysis was used to identify the potential down-stream signaling pathway regulated by IFI35. We further investigated the efficacy of the rhIFI35 protein in combination with immunotherapeutic treatment. The transcriptional and proteomic analysis of the activation and cytotoxicity of CD8 T cells in human cancer samples demonstrated that IFI35 expression is correlated with increased CD8 T cell infiltration and predicted a better outcome in colorectal cancer. The number and cytotoxicity of CD8 T cells were significantly increased in IFI35-overexpressing tumors. Mechanistically, we identified that the IFNγ-STAT1-IRF7 axis stimulated IFI35 expression, and that IFI35-mediated regulation of CD8 T cell proliferation and cytotoxicity was dependent on PI3K/AKT/mTOR signaling pathway in vitro. Furthermore, IFI35 protein enhanced the efficacy of CAR-T cells against colorectal cancer cells. Our findings identify IFI35 as a new biomarker that can enhance the proliferation and function of CD8 T cells, as well as increase the efficacy of CAR-T cells against colorectal cancer cells.
AbstractList BackgroundA large proportion of the patients with cancer do not respond to immunotherapies. Recent studies suggested an important role for tumor-infiltrating cytotoxic T lymphocytes (CTL) in enhancing response to immunotherapy. Here, we aim to identify gene that induce proliferative and cytotoxic states of CD8+ T cells, and to investigate its effect on CAR-T cells against colorectal cancer.MethodsCorrelation between the expression of IFI35 with the activation and cytotoxicity of CD8+ T cells was assessed with TCGA and proteomic databases. Then we constructed murine colon cancer cells over-expressing IFI35 and tested their effect on anti-tumor immunity in both immunodeficient and immunocompetent mouse models. Flow cytometry and immunohistochemistry were performed to assess the immune microenvironment. Western blot analysis was used to identify the potential down-stream signaling pathway regulated by IFI35. We further investigated the efficacy of the rhIFI35 protein in combination with immunotherapeutic treatment.ResultsThe transcriptional and proteomic analysis of the activation and cytotoxicity of CD8+ T cells in human cancer samples demonstrated that IFI35 expression is correlated with increased CD8+ T cell infiltration and predicted a better outcome in colorectal cancer. The number and cytotoxicity of CD8+ T cells were significantly increased in IFI35-overexpressing tumors. Mechanistically, we identified that the IFNγ-STAT1-IRF7 axis stimulated IFI35 expression, and that IFI35-mediated regulation of CD8+ T cell proliferation and cytotoxicity was dependent on PI3K/AKT/mTOR signaling pathway in vitro. Furthermore, IFI35 protein enhanced the efficacy of CAR-T cells against colorectal cancer cells.ConclusionOur findings identify IFI35 as a new biomarker that can enhance the proliferation and function of CD8+ T cells, as well as increase the efficacy of CAR-T cells against colorectal cancer cells.
Abstract Background A large proportion of the patients with cancer do not respond to immunotherapies. Recent studies suggested an important role for tumor-infiltrating cytotoxic T lymphocytes (CTL) in enhancing response to immunotherapy. Here, we aim to identify gene that induce proliferative and cytotoxic states of CD8+ T cells, and to investigate its effect on CAR-T cells against colorectal cancer. Methods Correlation between the expression of IFI35 with the activation and cytotoxicity of CD8+ T cells was assessed with TCGA and proteomic databases. Then we constructed murine colon cancer cells over-expressing IFI35 and tested their effect on anti-tumor immunity in both immunodeficient and immunocompetent mouse models. Flow cytometry and immunohistochemistry were performed to assess the immune microenvironment. Western blot analysis was used to identify the potential down-stream signaling pathway regulated by IFI35. We further investigated the efficacy of the rhIFI35 protein in combination with immunotherapeutic treatment. Results The transcriptional and proteomic analysis of the activation and cytotoxicity of CD8+ T cells in human cancer samples demonstrated that IFI35 expression is correlated with increased CD8+ T cell infiltration and predicted a better outcome in colorectal cancer. The number and cytotoxicity of CD8+ T cells were significantly increased in IFI35-overexpressing tumors. Mechanistically, we identified that the IFNγ-STAT1-IRF7 axis stimulated IFI35 expression, and that IFI35-mediated regulation of CD8+ T cell proliferation and cytotoxicity was dependent on PI3K/AKT/mTOR signaling pathway in vitro. Furthermore, IFI35 protein enhanced the efficacy of CAR-T cells against colorectal cancer cells. Conclusion Our findings identify IFI35 as a new biomarker that can enhance the proliferation and function of CD8+ T cells, as well as increase the efficacy of CAR-T cells against colorectal cancer cells. Graphical Abstract
A large proportion of the patients with cancer do not respond to immunotherapies. Recent studies suggested an important role for tumor-infiltrating cytotoxic T lymphocytes (CTL) in enhancing response to immunotherapy. Here, we aim to identify gene that induce proliferative and cytotoxic states of CD8+ T cells, and to investigate its effect on CAR-T cells against colorectal cancer.BACKGROUNDA large proportion of the patients with cancer do not respond to immunotherapies. Recent studies suggested an important role for tumor-infiltrating cytotoxic T lymphocytes (CTL) in enhancing response to immunotherapy. Here, we aim to identify gene that induce proliferative and cytotoxic states of CD8+ T cells, and to investigate its effect on CAR-T cells against colorectal cancer.Correlation between the expression of IFI35 with the activation and cytotoxicity of CD8+ T cells was assessed with TCGA and proteomic databases. Then we constructed murine colon cancer cells over-expressing IFI35 and tested their effect on anti-tumor immunity in both immunodeficient and immunocompetent mouse models. Flow cytometry and immunohistochemistry were performed to assess the immune microenvironment. Western blot analysis was used to identify the potential down-stream signaling pathway regulated by IFI35. We further investigated the efficacy of the rhIFI35 protein in combination with immunotherapeutic treatment.METHODSCorrelation between the expression of IFI35 with the activation and cytotoxicity of CD8+ T cells was assessed with TCGA and proteomic databases. Then we constructed murine colon cancer cells over-expressing IFI35 and tested their effect on anti-tumor immunity in both immunodeficient and immunocompetent mouse models. Flow cytometry and immunohistochemistry were performed to assess the immune microenvironment. Western blot analysis was used to identify the potential down-stream signaling pathway regulated by IFI35. We further investigated the efficacy of the rhIFI35 protein in combination with immunotherapeutic treatment.The transcriptional and proteomic analysis of the activation and cytotoxicity of CD8+ T cells in human cancer samples demonstrated that IFI35 expression is correlated with increased CD8+ T cell infiltration and predicted a better outcome in colorectal cancer. The number and cytotoxicity of CD8+ T cells were significantly increased in IFI35-overexpressing tumors. Mechanistically, we identified that the IFNγ-STAT1-IRF7 axis stimulated IFI35 expression, and that IFI35-mediated regulation of CD8+ T cell proliferation and cytotoxicity was dependent on PI3K/AKT/mTOR signaling pathway in vitro. Furthermore, IFI35 protein enhanced the efficacy of CAR-T cells against colorectal cancer cells.RESULTSThe transcriptional and proteomic analysis of the activation and cytotoxicity of CD8+ T cells in human cancer samples demonstrated that IFI35 expression is correlated with increased CD8+ T cell infiltration and predicted a better outcome in colorectal cancer. The number and cytotoxicity of CD8+ T cells were significantly increased in IFI35-overexpressing tumors. Mechanistically, we identified that the IFNγ-STAT1-IRF7 axis stimulated IFI35 expression, and that IFI35-mediated regulation of CD8+ T cell proliferation and cytotoxicity was dependent on PI3K/AKT/mTOR signaling pathway in vitro. Furthermore, IFI35 protein enhanced the efficacy of CAR-T cells against colorectal cancer cells.Our findings identify IFI35 as a new biomarker that can enhance the proliferation and function of CD8+ T cells, as well as increase the efficacy of CAR-T cells against colorectal cancer cells.CONCLUSIONOur findings identify IFI35 as a new biomarker that can enhance the proliferation and function of CD8+ T cells, as well as increase the efficacy of CAR-T cells against colorectal cancer cells.
A large proportion of the patients with cancer do not respond to immunotherapies. Recent studies suggested an important role for tumor-infiltrating cytotoxic T lymphocytes (CTL) in enhancing response to immunotherapy. Here, we aim to identify gene that induce proliferative and cytotoxic states of CD8.sup.+ T cells, and to investigate its effect on CAR-T cells against colorectal cancer. Correlation between the expression of IFI35 with the activation and cytotoxicity of CD8.sup.+ T cells was assessed with TCGA and proteomic databases. Then we constructed murine colon cancer cells over-expressing IFI35 and tested their effect on anti-tumor immunity in both immunodeficient and immunocompetent mouse models. Flow cytometry and immunohistochemistry were performed to assess the immune microenvironment. Western blot analysis was used to identify the potential down-stream signaling pathway regulated by IFI35. We further investigated the efficacy of the rhIFI35 protein in combination with immunotherapeutic treatment. The transcriptional and proteomic analysis of the activation and cytotoxicity of CD8.sup.+ T cells in human cancer samples demonstrated that IFI35 expression is correlated with increased CD8.sup.+ T cell infiltration and predicted a better outcome in colorectal cancer. The number and cytotoxicity of CD8.sup.+ T cells were significantly increased in IFI35-overexpressing tumors. Mechanistically, we identified that the IFN[gamma]-STAT1-IRF7 axis stimulated IFI35 expression, and that IFI35-mediated regulation of CD8.sup.+ T cell proliferation and cytotoxicity was dependent on PI3K/AKT/mTOR signaling pathway in vitro. Furthermore, IFI35 protein enhanced the efficacy of CAR-T cells against colorectal cancer cells. Our findings identify IFI35 as a new biomarker that can enhance the proliferation and function of CD8.sup.+ T cells, as well as increase the efficacy of CAR-T cells against colorectal cancer cells.
Background A large proportion of the patients with cancer do not respond to immunotherapies. Recent studies suggested an important role for tumor-infiltrating cytotoxic T lymphocytes (CTL) in enhancing response to immunotherapy. Here, we aim to identify gene that induce proliferative and cytotoxic states of CD8.sup.+ T cells, and to investigate its effect on CAR-T cells against colorectal cancer. Methods Correlation between the expression of IFI35 with the activation and cytotoxicity of CD8.sup.+ T cells was assessed with TCGA and proteomic databases. Then we constructed murine colon cancer cells over-expressing IFI35 and tested their effect on anti-tumor immunity in both immunodeficient and immunocompetent mouse models. Flow cytometry and immunohistochemistry were performed to assess the immune microenvironment. Western blot analysis was used to identify the potential down-stream signaling pathway regulated by IFI35. We further investigated the efficacy of the rhIFI35 protein in combination with immunotherapeutic treatment. Results The transcriptional and proteomic analysis of the activation and cytotoxicity of CD8.sup.+ T cells in human cancer samples demonstrated that IFI35 expression is correlated with increased CD8.sup.+ T cell infiltration and predicted a better outcome in colorectal cancer. The number and cytotoxicity of CD8.sup.+ T cells were significantly increased in IFI35-overexpressing tumors. Mechanistically, we identified that the IFN[gamma]-STAT1-IRF7 axis stimulated IFI35 expression, and that IFI35-mediated regulation of CD8.sup.+ T cell proliferation and cytotoxicity was dependent on PI3K/AKT/mTOR signaling pathway in vitro. Furthermore, IFI35 protein enhanced the efficacy of CAR-T cells against colorectal cancer cells. Conclusion Our findings identify IFI35 as a new biomarker that can enhance the proliferation and function of CD8.sup.+ T cells, as well as increase the efficacy of CAR-T cells against colorectal cancer cells. Graphical Keywords: IFI35, CD8.sup.+ T cells, Immunotherapy, Colorectal cancer
A large proportion of the patients with cancer do not respond to immunotherapies. Recent studies suggested an important role for tumor-infiltrating cytotoxic T lymphocytes (CTL) in enhancing response to immunotherapy. Here, we aim to identify gene that induce proliferative and cytotoxic states of CD8 T cells, and to investigate its effect on CAR-T cells against colorectal cancer. Correlation between the expression of IFI35 with the activation and cytotoxicity of CD8 T cells was assessed with TCGA and proteomic databases. Then we constructed murine colon cancer cells over-expressing IFI35 and tested their effect on anti-tumor immunity in both immunodeficient and immunocompetent mouse models. Flow cytometry and immunohistochemistry were performed to assess the immune microenvironment. Western blot analysis was used to identify the potential down-stream signaling pathway regulated by IFI35. We further investigated the efficacy of the rhIFI35 protein in combination with immunotherapeutic treatment. The transcriptional and proteomic analysis of the activation and cytotoxicity of CD8 T cells in human cancer samples demonstrated that IFI35 expression is correlated with increased CD8 T cell infiltration and predicted a better outcome in colorectal cancer. The number and cytotoxicity of CD8 T cells were significantly increased in IFI35-overexpressing tumors. Mechanistically, we identified that the IFNγ-STAT1-IRF7 axis stimulated IFI35 expression, and that IFI35-mediated regulation of CD8 T cell proliferation and cytotoxicity was dependent on PI3K/AKT/mTOR signaling pathway in vitro. Furthermore, IFI35 protein enhanced the efficacy of CAR-T cells against colorectal cancer cells. Our findings identify IFI35 as a new biomarker that can enhance the proliferation and function of CD8 T cells, as well as increase the efficacy of CAR-T cells against colorectal cancer cells.
ArticleNumber 47
Audience Academic
Author Lin, Yanyun
Chen, Dongwen
Zhou, Dawang
Chen, Yuan
Li, Peisi
Zhang, Xi
Zou, Yifeng
Lin, Zhensen
Cai, Jiawei
Lan, Ping
Ye, Shubiao
Huang, Wenfeng
Huang, Zhihong
Ke, Haoxian
Cheng, Yikan
Long, Jiahui
Author_xml – sequence: 1
  givenname: Peisi
  surname: Li
  fullname: Li, Peisi
– sequence: 2
  givenname: Dawang
  surname: Zhou
  fullname: Zhou, Dawang
– sequence: 3
  givenname: Dongwen
  surname: Chen
  fullname: Chen, Dongwen
– sequence: 4
  givenname: Yikan
  surname: Cheng
  fullname: Cheng, Yikan
– sequence: 5
  givenname: Yuan
  surname: Chen
  fullname: Chen, Yuan
– sequence: 6
  givenname: Zhensen
  surname: Lin
  fullname: Lin, Zhensen
– sequence: 7
  givenname: Xi
  surname: Zhang
  fullname: Zhang, Xi
– sequence: 8
  givenname: Zhihong
  surname: Huang
  fullname: Huang, Zhihong
– sequence: 9
  givenname: Jiawei
  surname: Cai
  fullname: Cai, Jiawei
– sequence: 10
  givenname: Wenfeng
  surname: Huang
  fullname: Huang, Wenfeng
– sequence: 11
  givenname: Yanyun
  surname: Lin
  fullname: Lin, Yanyun
– sequence: 12
  givenname: Haoxian
  surname: Ke
  fullname: Ke, Haoxian
– sequence: 13
  givenname: Jiahui
  surname: Long
  fullname: Long, Jiahui
– sequence: 14
  givenname: Yifeng
  surname: Zou
  fullname: Zou, Yifeng
– sequence: 15
  givenname: Shubiao
  surname: Ye
  fullname: Ye, Shubiao
– sequence: 16
  givenname: Ping
  orcidid: 0000-0002-5225-5027
  surname: Lan
  fullname: Lan, Ping
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37380972$$D View this record in MEDLINE/PubMed
BookMark eNp9UttuEzEQXaEieoEf4AFZ4qUS2tbX9e4TigKFqJWKUHi2HO84cbW7Dra3kK_gl3GSUtoKIT_MeHzO8czoHBcHgx-gKF4TfEZIXZ1HQhvalJiyEuOG4bJ6VhwRvr0SKg8e5IfFcYw3GBPR1PJFccgkq3Ej6VHxaz72PpQRTIAELZpdzJhA6-B7nyBuk85ZCDo5PyA9tMhskk_-pzNIm-RuXdogb9H0Q_0OzZGBrosorYIflyv0ZcYuzyeX8_N-fv0VRbccdOeGJVrrtPqhN8gNyPjOBzBJd8jowUB4WTy3uovw6i6eFN8uPs6nn8ur60-z6eSqNKLiqWzrlleWVjXm2uZpKqiMEBhrYaWWktOFFtoSAxUFYxeME2wMJURwbCVUkp0Us71u6_WNWgfX67BRXju1K_iwVDokZzpQwAjVmuNWLDjXYOuqqaHhLZcL0UoGWev9Xms9LnpoDQwp6O6R6OOXwa3U0t8qghlmjIuscHqnEPz3EWJSvYvbZeoB_BgVrXMPTdPkeFK8fQK98WPIm92halkzSuRf1FLnCdxgff7YbEXVROZFVQKLLersH6h8WuidyWazLtcfEd48nPR-xD9-ygC6B5jgYwxg7yEEq61p1d60KptW7Uyrqkyqn5CMSzvH5XZc9z_qb16K73M
CitedBy_id crossref_primary_10_1007_s10495_024_02015_7
crossref_primary_10_1080_19490976_2024_2423043
crossref_primary_10_1016_j_tranon_2024_102254
crossref_primary_10_1016_j_ccell_2024_11_006
crossref_primary_10_1016_j_intimp_2024_113850
crossref_primary_10_1007_s12672_024_01250_3
crossref_primary_10_1186_s12964_024_01654_2
crossref_primary_10_1021_acs_jproteome_3c00725
crossref_primary_10_1007_s12094_024_03692_1
crossref_primary_10_1016_j_ijbiomac_2024_138515
crossref_primary_10_1186_s12964_023_01455_z
crossref_primary_10_1016_j_bbcan_2024_189193
crossref_primary_10_1016_j_ijbiomac_2025_141013
crossref_primary_10_5306_wjco_v15_i8_1061
crossref_primary_10_1038_s41419_024_07215_2
crossref_primary_10_1089_cbr_2024_0061
crossref_primary_10_3390_vaccines13030292
crossref_primary_10_1186_s12935_024_03612_x
Cites_doi 10.1158/1078-0432.Ccr-13-0143
10.1002/cam4.2361
10.1038/nm.3967
10.1186/s13073-020-0721-z
10.1016/j.celrep.2021.110126
10.1038/s41423-021-00735-3
10.1158/1078-0432.Ccr-13-2462
10.1038/nrclinonc.2015.209
10.1016/j.immuni.2013.10.003
10.1038/ni.2005
10.1146/annurev.immunol.021908.132532
10.1186/s13059-016-1028-7
10.1093/nar/gkaa407
10.1073/pnas.2102642118
10.1038/s41467-017-00930-9
10.1093/emboj/17.10.2817
10.3389/fonc.2020.00586
10.1002/cam4.3828
10.1111/j.1365-2133.2010.09973.x
10.1128/jvi.02249-07
10.1186/s12935-021-01997-7
10.1038/s41577-018-0029-z
10.1038/s41591-018-0136-1
10.1158/0008-5472.Can-16-0549
10.1038/nature13954
10.1007/s00705-014-2147-7
10.1016/s1471-4906(02)02302-5
10.2174/1874467214666210301121432
10.1016/j.cell.2017.01.010
10.1016/j.immuni.2010.06.002
10.1101/cshperspect.a028423
10.1155/2010/956304
10.1200/JCO.2014.59.4358
10.1016/S0021-9258(17)42225-3
10.1016/j.brainres.2017.01.018
10.1080/14397595.2016.1270387
10.1073/pnas.1901987116
10.1016/j.ccell.2019.01.003
10.1038/s41588-020-0636-z
10.1158/1078-0432.CCR-15-2879
10.1128/jvi.00283-21
10.1056/NEJMoa1504542
10.1016/j.celrep.2016.12.019
10.1128/jvi.03202-13
10.1158/0008-5472.CAN-17-0307
10.1002/jcp.27782
10.1158/2326-6066.Cir-16-0019
10.1016/j.cell.2019.03.030
10.1016/j.immuni.2013.09.015
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QL
7QO
7QP
7T5
7TK
7TM
7U7
7U9
7X7
7XB
88E
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
8G5
ABJCF
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
GUQSH
H94
HCIFZ
K9.
L6V
LK8
M0S
M1P
M2O
M7N
M7P
M7S
MBDVC
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PTHSS
Q9U
RC3
7X8
5PM
DOA
DOI 10.1186/s12929-023-00930-6
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Toxicology Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
Materials Science & Engineering Collection
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Engineering Collection
Biological Sciences
ProQuest Health & Medical Collection
Medical Database ProQuest
Research Library
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Engineering Database
Research Library (Corporate)
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
Engineering Collection
ProQuest Central Basic
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
Acceso a contenido Full Text - Doaj
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Engineering Collection
Engineering Database
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
ProQuest Engineering Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Central Basic
Toxicology Abstracts
ProQuest SciTech Collection
ProQuest Medical Library
Materials Science & Engineering Collection
Immunology Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database

MEDLINE - Academic


MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1423-0127
EndPage 19
ExternalDocumentID oai_doaj_org_article_e312aa40d5b44aef8698e94d47b5d73e
PMC10303345
A755065057
37380972
10_1186_s12929_023_00930_6
Genre Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: Science and Technology Planning Project of Guangzhou
  grantid: 201902020009
– fundername: Key-Area Research and Development Program of Guangdong Province
  grantid: 2019B020229002
– fundername: ;
  grantid: 201902020009
– fundername: ;
  grantid: 2019B020229002
GroupedDBID ---
.86
0R~
29J
29K
2NJ
2WC
36B
4.4
5GY
5VS
7X7
88E
8FE
8FG
8FH
8FI
8FJ
8G5
AAFWJ
AAYXX
ABDBF
ABJCF
ABJNI
ABOCM
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADIMF
ADRAZ
ADUKV
AEAQA
AEGNC
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
AZQEC
B0M
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BGLVJ
BGNMA
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
CYUIP
D-I
DIK
DU5
DWQXO
E3Z
EAD
EAP
EBC
EBD
EBLON
EBS
EMB
EMK
EMOBN
EPL
ESX
F5P
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HCIFZ
HMCUK
HYE
IAO
IEA
IHE
IHR
INH
INR
ITC
IZQ
KDC
KQ8
L6V
LAK
LK8
M1P
M2O
M48
M4Y
M7P
M7S
ML~
NU0
O5R
O5S
OK1
P19
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PTHSS
RBZ
RHV
RNS
ROL
RPM
RPX
RRX
RSV
S27
SBL
SDH
SOJ
SV3
T13
TR2
TUS
UKHRP
VC2
WJK
WK8
~8M
~KM
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
M~E
NPM
PMFND
7QL
7QO
7QP
7T5
7TK
7TM
7U7
7U9
7XB
8FD
8FK
C1K
FR3
H94
K9.
M7N
MBDVC
P64
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
Q9U
RC3
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c564t-d8d46f26804af3736e6c5500a5f7a7742ba5af1ce62ecfb3410cc211540f7e673
IEDL.DBID M48
ISSN 1423-0127
1021-7770
IngestDate Wed Aug 27 01:16:05 EDT 2025
Thu Aug 21 18:37:48 EDT 2025
Mon Jul 21 11:00:15 EDT 2025
Fri Jul 25 19:22:38 EDT 2025
Tue Jun 17 21:26:01 EDT 2025
Tue Jun 10 20:08:02 EDT 2025
Wed Feb 19 02:23:28 EST 2025
Tue Jul 01 00:21:25 EDT 2025
Thu Apr 24 22:53:10 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords CD8+ T cells
IFI35
Immunotherapy
Colorectal cancer
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c564t-d8d46f26804af3736e6c5500a5f7a7742ba5af1ce62ecfb3410cc211540f7e673
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-5225-5027
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12929-023-00930-6
PMID 37380972
PQID 2838783217
PQPubID 54111
PageCount 19
ParticipantIDs doaj_primary_oai_doaj_org_article_e312aa40d5b44aef8698e94d47b5d73e
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10303345
proquest_miscellaneous_2831299928
proquest_journals_2838783217
gale_infotracmisc_A755065057
gale_infotracacademiconefile_A755065057
pubmed_primary_37380972
crossref_primary_10_1186_s12929_023_00930_6
crossref_citationtrail_10_1186_s12929_023_00930_6
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-06-28
PublicationDateYYYYMMDD 2023-06-28
PublicationDate_xml – month: 06
  year: 2023
  text: 2023-06-28
  day: 28
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Basel
– name: London
PublicationTitle Journal of biomedical science
PublicationTitleAlternate J Biomed Sci
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References FO Martinez (930_CR27) 2009; 27
N Kumar (930_CR31) 2021; 14
W Hugo (930_CR45) 2017; 168
K Lee (930_CR36) 2010; 32
Q Hu (930_CR19) 2021; 10
A Weiss (930_CR34) 1991; 3
X Chi (930_CR18) 2019; 8
T Li (930_CR40) 2017; 77
MJ Smyth (930_CR3) 2016; 13
H Negishi (930_CR38) 2018; 10
J Guinney (930_CR28) 2015; 21
Z Zhou (930_CR6) 2019; 116
B Li (930_CR41) 2016; 17
K Shirai (930_CR49) 2017; 1658
A Mantovani (930_CR26) 2002; 23
T Li (930_CR39) 2020; 48
Z Xiahou (930_CR15) 2017; 8
A Das (930_CR13) 2014; 88
Y Hu (930_CR17) 2021; 21
H Yang (930_CR42) 2021; 95
Y Guan (930_CR9) 2020; 10
Y Yu (930_CR48) 2021; 37
M Cartellieri (930_CR46) 2010; 2010
FC Bange (930_CR10) 1994; 269
G Bindea (930_CR21) 2013; 39
E Becht (930_CR29) 2016; 22
AW Turksma (930_CR5) 2016; 22
LB Ivashkiv (930_CR37) 2018; 18
PC Tumeh (930_CR8) 2014; 515
M Rincón (930_CR33) 1998; 17
S Vasaikar (930_CR22) 2019; 177
X Jing (930_CR43) 2021; 118
P Jiang (930_CR7) 2018; 24
PA Ott (930_CR1) 2013; 19
P Charoentong (930_CR20) 2017; 18
T Nathanson (930_CR24) 2017; 5
TN Gide (930_CR25) 2019; 35
W Du (930_CR50) 2022; 19
J Fu (930_CR23) 2020; 12
ME Rodriguez-Ruiz (930_CR4) 2016; 76
L Zhang (930_CR14) 2017; 27
AL Garfall (930_CR47) 2015; 373
K Yang (930_CR35) 2013; 39
W Zheng (930_CR11) 2014; 159
J Tan (930_CR12) 2008; 82
MA Postow (930_CR2) 2015; 33
GM Delgoffe (930_CR32) 2011; 12
B Farhood (930_CR44) 2019; 234
HO Lee (930_CR30) 2020; 52
RG Pomerantz (930_CR16) 2010; 163
References_xml – volume: 19
  start-page: 5300
  year: 2013
  ident: 930_CR1
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.Ccr-13-0143
– volume: 8
  start-page: 4753
  year: 2019
  ident: 930_CR18
  publication-title: Cancer Med
  doi: 10.1002/cam4.2361
– volume: 21
  start-page: 1350
  year: 2015
  ident: 930_CR28
  publication-title: Nat Med
  doi: 10.1038/nm.3967
– volume: 12
  start-page: 21
  year: 2020
  ident: 930_CR23
  publication-title: Genome Med
  doi: 10.1186/s13073-020-0721-z
– volume: 37
  year: 2021
  ident: 930_CR48
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2021.110126
– volume: 19
  start-page: 23
  year: 2022
  ident: 930_CR50
  publication-title: Cell Mol Immunol
  doi: 10.1038/s41423-021-00735-3
– volume: 22
  start-page: 346
  year: 2016
  ident: 930_CR5
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.Ccr-13-2462
– volume: 13
  start-page: 143
  year: 2016
  ident: 930_CR3
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2015.209
– volume: 39
  start-page: 782
  year: 2013
  ident: 930_CR21
  publication-title: Immunity
  doi: 10.1016/j.immuni.2013.10.003
– volume: 12
  start-page: 295
  year: 2011
  ident: 930_CR32
  publication-title: Nat Immunol
  doi: 10.1038/ni.2005
– volume: 27
  start-page: 451
  year: 2009
  ident: 930_CR27
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev.immunol.021908.132532
– volume: 17
  start-page: 174
  year: 2016
  ident: 930_CR41
  publication-title: Genome Biol
  doi: 10.1186/s13059-016-1028-7
– volume: 48
  start-page: W509
  year: 2020
  ident: 930_CR39
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkaa407
– volume: 118
  year: 2021
  ident: 930_CR43
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.2102642118
– volume: 8
  start-page: 950
  year: 2017
  ident: 930_CR15
  publication-title: Nat Commun
  doi: 10.1038/s41467-017-00930-9
– volume: 17
  start-page: 2817
  year: 1998
  ident: 930_CR33
  publication-title: Embo J
  doi: 10.1093/emboj/17.10.2817
– volume: 10
  start-page: 586
  year: 2020
  ident: 930_CR9
  publication-title: Front Oncol
  doi: 10.3389/fonc.2020.00586
– volume: 10
  start-page: 3129
  year: 2021
  ident: 930_CR19
  publication-title: Cancer Med
  doi: 10.1002/cam4.3828
– volume: 163
  start-page: 1090
  year: 2010
  ident: 930_CR16
  publication-title: Br J Dermatol
  doi: 10.1111/j.1365-2133.2010.09973.x
– volume: 82
  start-page: 4275
  year: 2008
  ident: 930_CR12
  publication-title: J Virol
  doi: 10.1128/jvi.02249-07
– volume: 21
  start-page: 290
  year: 2021
  ident: 930_CR17
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-021-01997-7
– volume: 18
  start-page: 545
  year: 2018
  ident: 930_CR37
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-018-0029-z
– volume: 24
  start-page: 1550
  year: 2018
  ident: 930_CR7
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0136-1
– volume: 76
  start-page: 5994
  year: 2016
  ident: 930_CR4
  publication-title: Can Res
  doi: 10.1158/0008-5472.Can-16-0549
– volume: 3
  start-page: 313
  year: 1991
  ident: 930_CR34
  publication-title: Semin Immunol
– volume: 515
  start-page: 568
  year: 2014
  ident: 930_CR8
  publication-title: Nature
  doi: 10.1038/nature13954
– volume: 159
  start-page: 2925
  year: 2014
  ident: 930_CR11
  publication-title: Arch Virol
  doi: 10.1007/s00705-014-2147-7
– volume: 23
  start-page: 549
  year: 2002
  ident: 930_CR26
  publication-title: Trends Immunol
  doi: 10.1016/s1471-4906(02)02302-5
– volume: 14
  start-page: 823
  year: 2021
  ident: 930_CR31
  publication-title: Curr Mol Pharmacol
  doi: 10.2174/1874467214666210301121432
– volume: 168
  start-page: 542
  year: 2017
  ident: 930_CR45
  publication-title: Cell
  doi: 10.1016/j.cell.2017.01.010
– volume: 32
  start-page: 743
  year: 2010
  ident: 930_CR36
  publication-title: Immunity
  doi: 10.1016/j.immuni.2010.06.002
– volume: 10
  year: 2018
  ident: 930_CR38
  publication-title: Cold Spring Harb Perspect Biol
  doi: 10.1101/cshperspect.a028423
– volume: 2010
  year: 2010
  ident: 930_CR46
  publication-title: J Biomed Biotechnol
  doi: 10.1155/2010/956304
– volume: 33
  start-page: 1974
  year: 2015
  ident: 930_CR2
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.59.4358
– volume: 269
  start-page: 1091
  year: 1994
  ident: 930_CR10
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(17)42225-3
– volume: 1658
  start-page: 60
  year: 2017
  ident: 930_CR49
  publication-title: Brain Res
  doi: 10.1016/j.brainres.2017.01.018
– volume: 27
  start-page: 1010
  year: 2017
  ident: 930_CR14
  publication-title: Mod Rheumatol
  doi: 10.1080/14397595.2016.1270387
– volume: 116
  start-page: 11972
  year: 2019
  ident: 930_CR6
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1901987116
– volume: 35
  start-page: 238
  year: 2019
  ident: 930_CR25
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2019.01.003
– volume: 52
  start-page: 594
  year: 2020
  ident: 930_CR30
  publication-title: Nat Genet
  doi: 10.1038/s41588-020-0636-z
– volume: 22
  start-page: 4057
  year: 2016
  ident: 930_CR29
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-2879
– volume: 95
  year: 2021
  ident: 930_CR42
  publication-title: J Virol
  doi: 10.1128/jvi.00283-21
– volume: 373
  start-page: 1040
  year: 2015
  ident: 930_CR47
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1504542
– volume: 18
  start-page: 248
  year: 2017
  ident: 930_CR20
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2016.12.019
– volume: 88
  start-page: 3103
  year: 2014
  ident: 930_CR13
  publication-title: J Virol
  doi: 10.1128/jvi.03202-13
– volume: 77
  start-page: e108
  year: 2017
  ident: 930_CR40
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-17-0307
– volume: 234
  start-page: 8509
  year: 2019
  ident: 930_CR44
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.27782
– volume: 5
  start-page: 84
  year: 2017
  ident: 930_CR24
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.Cir-16-0019
– volume: 177
  start-page: 1035
  year: 2019
  ident: 930_CR22
  publication-title: Cell
  doi: 10.1016/j.cell.2019.03.030
– volume: 39
  start-page: 1043
  year: 2013
  ident: 930_CR35
  publication-title: Immunity
  doi: 10.1016/j.immuni.2013.09.015
SSID ssj0015987
Score 2.490296
Snippet A large proportion of the patients with cancer do not respond to immunotherapies. Recent studies suggested an important role for tumor-infiltrating cytotoxic T...
Background A large proportion of the patients with cancer do not respond to immunotherapies. Recent studies suggested an important role for tumor-infiltrating...
BackgroundA large proportion of the patients with cancer do not respond to immunotherapies. Recent studies suggested an important role for tumor-infiltrating...
Abstract Background A large proportion of the patients with cancer do not respond to immunotherapies. Recent studies suggested an important role for...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 47
SubjectTerms 1-Phosphatidylinositol 3-kinase
AKT protein
Animal models
Animals
Antibodies
Anticancer properties
Antigens
Antineoplastic Agents
Biomarkers
CD8 antigen
CD8+ T cells
CD8-Positive T-Lymphocytes
Cell culture
Cell growth
Cell proliferation
Colon cancer
Colonic Neoplasms
Colorectal cancer
Colorectal carcinoma
Cytotoxicity
Effectiveness
Flow cytometry
Humans
IFI35
Immunodeficiency
Immunohistochemistry
Immunotherapy
Interferon regulatory factor 7
Laboratory animals
Lymphocytes
Lymphocytes T
Metastases
Mice
Microenvironments
Phosphatidylinositol 3-Kinases
Proteins
Proteomics
Proto-Oncogene Proteins c-akt - genetics
Signal Transduction
Stat1 protein
T cells
TOR protein
TOR Serine-Threonine Kinases - genetics
Toxicity
Tumor Microenvironment
Tumors
γ-Interferon
SummonAdditionalLinks – databaseName: Acceso a contenido Full Text - Doaj
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yoPgien5VT4kg-HCE3c1X08fzdLlVTkX24N5Cmibcwl177HbR_Sv8l51Ju8sWQV98K80UkswkM9NMfj9C3pZy4oV3FYNgnTPEmWQmljnzOq90iHES0-n5-Rd9diE_XarLPaovrAnr4IG7iRsFMeHOyXGlSildiEYXJhSyknmpqlwE3H3B522Tqf78QEEqvb0iY_RoBV6NFwz8E8MUHhKmgRtKaP1_7sl7TmlYMLnngaYPyYM-dKQnXZcfkTuhPiR3OzLJzSG5d94fkz8mv-brm2bJVhgSQkRJZ9OZUPQ2Vd6FFT5cY0VLUgp1dUX9pm3a5ufCU7zngHQStIn09IM5pnOK__ZXtCf0od9m4vMIIsPRzfzrd4rlHw5vtFOkNv7hNnRRUwTCxo0UOuvRqJZPyMX04_z0jPXMC8wrLVtWmUrqyLUZSxdFLnTQHlKZsVMxdxAw8tIpFyc-aB58LMETjr3niOwzjnnQuXhKDuqmDs8JFWURIOYKuqiMFFI5xJNXPAgluAfvmJHJVhHW97DkyI5xbVN6YrTtlGdBeTYpz-qMHO--ue1AOf4q_R71u5NEQO30AszM9mZm_2VmGXmH1mFx2UP3vOtvL8AgEUDLnuQwPxqzvYwcDSRhufph89a-bL9drCzEeCZHzihofrNrxi-xBK4OzTrJwNCKgpuMPOvMcTckhKdCHKaMmIGhDsY8bKkXVwlMHGnmBOjlxf-YpZfkPk-LTDNujshBu1yHVxC0teXrtD5_AwdAPME
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLZgCMQLgnELDGQkJB4mq63t2M4TGoNqBQ0Q6qS9WY5jQ6UtKU0r6K_gL3OOm5ZFSHuLYkeyc47PxT7-PkJel3LkhXcVg2CdM8SZZCaWmnmlKxViHMV0en76WZ2cyY_n-Xm34dZ2ZZVbm5gMddV43CMfgBs0Gml19Nv5T4asUXi62lFo3CS3ELoMS7r0-S7hAk-dCPKQvRqiSD3cXpoxatCCn-MFA4_FMKmHFKrnmBJ-__9W-oqb6pdQXvFJ4_vkXhdM0qON9B-QG6HeJ7c39JLrfXLntDs4f0j-TFeXzYK1GCRCjEkn44nI6TzV4oUWHy6wxiWJibq6on69bJbN75mnePMBCSZoE-nxe3NIpxR3-1vaUfzQrxPxaQCx4uBy-uUbxYIQh3fcKZId_3JrOqspQmOjaYXBelSzxSNyNv4wPT5hHRcD87mSS1aZSqrIlRlKF4UWKigPyc3Q5VE7CCF56XIXRz4oHnwswTcOveeI9TOMOigtHpO9uqnDU0JFWQSIwoIqKiOFzB0izOc8iFxwD_4yI6OtIKzvgMqRL-PCpoTFKLsRngXh2SQ8qzJyuPtmvoHpuLb3O5TvridCbKcXzeK77VasDWLEnZPDKi-ldCEaVZhQyErqMq-0CBl5g9ph0RDA8Lzr7jPAJBFSyx5p-D8K87-MHPR6wgL2_eatftnOgLT2n7pn5NWuGb_Eorg6NKvUB6ZWFNxk5MlGHXdTQsAqRGbKiOkpam_O_ZZ69iPBiyPxnAC5PLt-XM_JXZ6Wj2LcHJC95WIVXkCAtixfplX4F3sMNZ8
  priority: 102
  providerName: ProQuest
Title Tumor-secreted IFI35 promotes proliferation and cytotoxic activity of CD8+ T cells through PI3K/AKT/mTOR signaling pathway in colorectal cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/37380972
https://www.proquest.com/docview/2838783217
https://www.proquest.com/docview/2831299928
https://pubmed.ncbi.nlm.nih.gov/PMC10303345
https://doaj.org/article/e312aa40d5b44aef8698e94d47b5d73e
Volume 30
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELf2IRAvCMZXYVRGQuJhCk1sx3YeENrGuhXUMU2t1LfIcRyo1CWjH2L9K_iXuXPTsogJ8RJFtVPlcne5u_j8-xHyNhOR5dbkASTrLECcyUAXmQqsVLl0RREVfvW8fy7PhuLzKB5tkTXdUf0AZ3eWdsgnNZxO3t_8WH4Eh__gHV7LzgxiFksCiD4BFuhQDm2TXYhMCh21L_6sKsSJJ8xDNmvIKlW43kRz5380ApXH8__7rX0rbDVbKm_FqO4j8rBOLunhyhoeky1X7pF7K7rJ5R65368X0p-QX4PFVTUNZpg0Qs5Je90ej-m1781zMzyZYM-LVxs1ZU7tcl7Nq5uxpbgTAgknaFXQ40_6gA4ofv2f0Zryh170-JcO5I6dq8HXS4oNIgb3vFMkP_5plnRcUoTKxlct3KxFs5s-JcPuyeD4LKi5GQIbSzEPcp0LWTCpQ2EKrrh00kKxE5q4UAZSSpaZ2BSRdZI5W2QQK0NrGWL_hIVyUvFnZKesSveCUJ4lDrIyJ5NcCy5ig4jzMXM85sxC_GyRaK2I1NbA5cifMUl9AaNlulJeCspLvfJS2SIHm2uuV7Ad_5x9hPrdzETIbf9DNf2W1h6cOh4xY0SYx5kQxhVaJtolIhcqi3PFXYu8Q-tI0VTh9qyp9zeAkAixlR4qeD4S68EW2W_MBIe2zeG1faVrf0ghC9QKWaVg-M1mGK_EJrnSVQs_B0RLEqZb5PnKHDciIYAVIjW1iG4YakPm5kg5_u7hxpGIjoNeXv63gK_IA-Y9SQZM75Od-XThXkPuNs_aZFuNFBx197RNdo9Ozi8u2_47CBxPR1HbO-xvIGNCJw
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEJcXBOMWGGAkEA9T1NRObOcBobFRtXQdCHVS3zzHcaDSlpReNPor-Cf8Rs5x07IIaW97q2qnsnuOz_kcH38fIW-yuG25NXkIYJ2FyDMZqiKToRUyF64o2oU_PR8ci-5J_HmUjLbIn_VdGCyrXMdEH6jzyuI78hakQSVRVkd-mPwMUTUKT1fXEhort-i75QVs2Wbve4dg37eMdT4ND7phrSoQ2kTE8zBXeSwKJlQUm4JLLpywANMjkxTSABhimUlM0bZOMGeLDKJ8ZC1D1pqokE5IDr97g9yExBvhipKjzQYPkIEX5EO1bECtMlpf0lGiNYO8ytIQMmSILxFgy9ZIhF4v4P-scCktNks2L-XAzn1yrwavdH_lbQ_Ilit3yK2VnOVyh9we1Af1D8nv4eK8moYzBKWAaWmv0-MJnfjaPzfDD2dYU-Pdgpoyp3Y5r-bVr7GleNMCBS1oVdCDQ7VHhxRPF2a0lhSiX3u83wJs2joffvlGsQDF4J16iuLKF2ZJxyVFKm4M5TBYi249fUROrsVKj8l2WZXuKaE8Sx2gPifSXMU8Tgwy2ifM8YQzC_k5IO21IbStidFRn-NM-w2SEnplPA3G0954WgRkb_PMZEULcmXvj2jfTU-k9PZfVNPvuo4Q2vE2MyaO8iSLY-MKJVLl0jiPZZbkkruAvEPv0Bh4YHjW1PcnYJJI4aX3Jfw_AvebAdlt9ISAYZvNa__SdcCa6X_LKyCvN834JBbhla5a-D4wtTRlKiBPVu64mRISZCETVEBUw1Ebc262lOMfns4che442OXZ1eN6Re50h4MjfdQ77j8nd5lfSiJkapdsz6cL9wLA4Tx76VckJafXHQL-AsWLcio
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tumor-secreted+IFI35+promotes+proliferation+and+cytotoxic+activity+of+CD8%2B+T+cells+through+PI3K%2FAKT%2FmTOR+signaling+pathway+in+colorectal+cancer&rft.jtitle=Journal+of+biomedical+science&rft.au=Li%2C+Peisi&rft.au=Zhou%2C+Dawang&rft.au=Chen%2C+Dongwen&rft.au=Cheng%2C+Yikan&rft.date=2023-06-28&rft.pub=BioMed+Central+Ltd&rft.issn=1021-7770&rft.volume=30&rft.issue=1&rft_id=info:doi/10.1186%2Fs12929-023-00930-6&rft.externalDocID=A755065057
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1423-0127&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1423-0127&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1423-0127&client=summon